Estelle
Commercial- Indications
- Contraception
Company intelligence / Profile preview
Mithra Pharmaceuticals SA
Liege, Belgiummithra.com ↗
- Ownership
- Private
- Employees
- ~270
- Development stage
- Commercial
01
Overview
Mithra filed for bankruptcy in 2024 and sold its remaining assets for $188.2 million. Prior to bankruptcy, the company had successfully launched Estelle, the first estetrol-based contraceptive pill in 2021, and was developing Donesta for menopause symptoms.
- Therapeutic areas
- Women's HealthOncologyEndocrinologyInfectious Diseases
- Modalities
- Small moleculesPeptidesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Gedeon RichterBCI Pharma
Beyond the preview
Go deeper on Mithra Pharmaceuticals SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mithra Pharmaceuticals SA.